Metronidazole Research: Historical Developments and Future Directions
DOI:
https://doi.org/10.14738/bjhr.1301.19792Keywords:
Metronidazole, Bibliometric Analysis, VOS viewer, Scopus, Cite SpaceAbstract
Metronidazole is widely used around the world to treat anaerobic, parasitic, and bacterial infections. Yet, despite its significance, a comprehensive review that weaves together its historical Breakthroughs and charts a course for future research is still missing. This study used bibliometric analysis to comprehensively examine the global landscape of Metronidazole research, based on publications from the Scopus database between 1960 and 2024. Data were analyzed using R software, VOS viewer, and Cite Space to explore qualitative and quantitative trends. Results: The first article published in 1960, the number of scientific publications has increased, especially after 1985. 6,172 publications were identified with 160,000 citations, showing a steady annual growth rate of 6.26%, reflecting a vibrant and steadily growing field. Notably, publication rates soared after 2024. WANG was the most prolific author, while China and the United States led in productivity, with 13% international collaboration. The Journal of Antimicrobial Chemotherapy is the leading journal in terms of publication venue. Network analysis spotlighted Metronidazole, tetracycline, and vancomycin as central antibiotics. Highly cited studies focused on Clostridium difficile infection, Helicobacter pylori eradication, and bacterial vaginosis. Over time, research themes have shifted from traditional pharmacology and microbiology to innovative areas such as nanotechnology, biosensing, computational modeling, and green chemistry. The research on Metronidazole shifting into four promising directions for future exploration: harnessing artificial intelligence to predict resistance, leveraging computational tools to uncover new applications, embracing green chemistry to minimize environmental impact, and advancing precision medicine through genetic biomarkers.
References
D. Leitsch, “A review on metronidazole: an old warhorse in antimicrobial chemotherapy,” Parasitology, vol. 146, no. 9, pp. 1167–1178, 2019, doi: DOI: 10.1017/S0031182017002025.
P. DUREL, J. COUTURE, P. COLLART, and C. GIROT, “Flagyl (metronidazole).,” Br. J. Vener. Dis., vol. 36, no. 3, pp. 154–162, Sep. 1960, doi: 10.1136/sti.36.3.154. Scholar Publishing
D. Mastronicola et al., “Giardia intestinalis escapes oxidative stress by colonizing the small intestine: A molecular hypothesis,” IUBMB Life, vol. 63, no. 1, pp. 21–25, Jan. 2011, doi: https://doi.org/10.1002/iub.409.
A. H. Holmes et al., “Understanding the mechanisms and drivers of antimicrobial resistance,” Lancet, vol. 387, no. 10014, pp. 176–187, 2016, doi: 10.1016/S0140-6736(15)00473-0.
R. Sobel and J. D. Sobel, “Metronidazole for the treatment of vaginal infections,” Expert Opin. Pharmacother., vol. 16, no. 7, pp. 1109–1115, May 2015, doi: 10.1517/14656566.2015.1035255.
D. G. Ferris, M. S. Litaker, L. Woodward, D. Mathis, and J. B. T.-J. of F. P. Hendrich, “Treatment of bacterial vaginosis: a comparison of oral metronidazole, metronidazole vaginal gel, and clindamycin vaginal cream,” vol. 41, no. 5, p. 443+, Aug. 1995, [Online]. Available: https://link.gale.com/apps/doc/A17815438/AONE?u=anon~96984c45&
S. Löfmark, C. Edlund, and C. E. Nord, “Metronidazole is still the drug of choice for treatment of anaerobic infections,” in Clinical Infectious Diseases, 2010, vol. 50, no. SUPP.1, pp. S16–S23. doi: 10.1086/647939.
C. S. Bradshaw et al., “High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence,” J. Infect. Dis., vol. 193, no. 11, pp. 1478–1486, 2006, doi: 10.1086/503780.
L. Sutherland et al., “Double blind, placebo controlled trial of metronidazole in Crohn’s disease,” Gut, vol. 32, no. 9, pp. 1071–1075, 1991, doi: 10.1136/gut.32.9.1071.
F. A. Zar, S. R. Bakkanagari, K. M. L. S. T. Moorthi, and M. B. Davis, “A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity,” Clin. Infect. Dis., vol. 45, no. 3, pp. 302–307, 2007, doi: 10.1086/519265.
E. Hentschel et al., “Effect of Ranitidine and Amoxicillin plus Metronidazole on the Eradication of Helicobacter pylori and the Recurrence of Duodenal Ulcer,” N. Engl. J. Med.,
J. C. Carey et al., “Metronidazole to prevent preterm delivery in pregnant women with asymptomatic bacterial vaginosis,” N. Engl. J. Med., vol. 342, no. 8, pp. 534–540, 2000, doi: 10.1056/NEJM200002243420802.
P. Rutgeerts et al., “Controlled trial of metronidazole treatment for prevention of crohn’s recurrence after ileal resection,” Gastroenterology, vol. 108, no. 6, pp. 1617–1621, 1995, doi: 10.1016/0016-5085(95)90121-3.
J. C. Hauth, R. L. Goldenberg, W. W. Andrews, M. B. Dubard, and R. L. Copper, “Reduced incidence of preterm delivery with metronidazole and erythromycin in women with bacterial vaginosis,” N. Engl. J. Med., vol. 333, no. 26, pp. 1732–1736, 1995, doi: 10.1056/NEJM199512283332603.
D. Teasley et al., “PROSPECTIVE RANDOMISED TRIAL OF METRONIDAZOLE VERSUS VANCOMYCIN FOR CLOSTRIDIUM-DIFFICILE-ASSOCIATED DIARRHOEA AND COLITIS,” Lancet, vol. 322, no. 8358, pp. 1043–1046, 1983, doi: 10.1016/S0140-6736(83)91036-X.
P. Malfertheiner et al., “Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: A randomised, open-label, non-inferiority, phase 3 trial,” Lancet, vol. 377, no. 9769, pp. 905–913, 2011, doi: 10.1016/S0140-6736(11)60020-2. Scholar Publishing
M. Yabré et al., “Qualitative and quantitative analysis of metronidazole formulations using a low-cost near infrared transmission spectrophotometer and chemometric tools,” Anal. Methods, vol. 17, no. 10, pp. 2312–2320, 2025, doi: 10.1039/D4AY02251C.
S. A. Dingsdag and N. Hunter, “Metronidazole: an update on metabolism, structurecytotoxicity and resistance mechanisms.,” J. Antimicrob. Chemother., vol. 73, no. 2, pp. 265–279, Feb. 2018, doi: 10.1093/jac/dkx351.
F. Hu and B. Su, “Global research trends of drug resistance in Trichomonas vaginalis : A bibliometric analysis via CiteSpace,” vol. 19, no. July, pp. 36–45, 2025, doi: 10.5897/AJPP2025.5436.
T. H. Musa, J. Kawuki, and H. H. Musa, “Bibliometric analysis of the African Health Sciences’ research indexed in Web of Science and Scopus,” Afr. Health Sci., vol. 22, no. 2, pp. 704–716, 2022, doi: 10.4314/ahs.v22i2.80.
H. Mokhtari, S. Barkhan, D. Haseli, and M. K. Saberi, “A bibliometric analysis and visualization of the Journal of Documentation: 1945–2018,” J. Doc., vol. 77, no. 1, pp. 69–92, Aug. 2020, doi: 10.1108/JD-08-2019-0165.
T. H. Musa, A. A. I. Arbab, and H. H. Musa, “Bibliometric analysis of asian Pacific Journal of Tropical Medicine from 2008 to 2019,” Int. J. Public Heal. Sci., vol. 9, no. 2, pp. 129–136, 2020, doi: 10.11591/ijphs.v9i2.20430.
T. Y. Akintunde et al., “Bibliometric Analysis of Global Scientific Literature on effects of COVID-19 Pandemic on Mental Health,” Asian J. Psychiatr., p. 102753, Jul. 2021, doi: 10.1016/J.AJP.2021.102753.
T. H. Musa and T. Y. Akintunde, “Original paper Global Scientific Research Output on Sickle Cell Disease : A Comprehensive Bibliometric Analysis of Web of Science Publication,” Sci. African, p. e00774, 2021, doi: 10.1016/j.sciaf.2021.e00774.
I. H. Musa et al., “Arti fi cial Intelligence and Machine Learning in Cancer Research : A Systematic and Thematic Analysis of the Top 100 Cited Articles Indexed in Scopus Database,” 2022, doi: 10.1177/10732748221095946.
T. H. Musa et al., “A Bibliometric Analysis of Global Scientific Research on Scrub Typhus,” Biomed Res. Int., 2020, doi: 10.1155/2020/5737893.
H. H. Musa and T. H. Musa, “A systematic and thematic analysis of the top 100 cited articles on mRNA vaccine indexed in Scopus database.,” Hum. Vaccin. Immunother., vol. 18, no. 6, p. 2135927, Nov. 2022, doi: 10.1080/21645515.2022.2135927.
Y. Zhang, C. Shaojun, T. Y. Akintunde, E. F. Okagbue, S. O. Isangha, and T. H. Musa, “Life course and mental health: a thematic and systematic review,” Front. Psychol., vol. 15, no. September, 2024, doi: 10.3389/fpsyg.2024.1329079.
H. H. Musa, T. H. Musa, I. H. Musa, and I. H. Musa, “Global scientific research progress in mycetoma: a bibliometric analysis,” Trans. R. Soc. Trop. Med. Hyg., pp. 1–13, 2021, doi: 10.1093/trstmh/trab072.
J. F. Burnham, “Scopus database: A review,” Biomedical Digital Libraries. 2006. doi: 10.1186/1742-5581-3-1.
M. Aria and C. Cuccurullo, “bibliometrix: An R-tool for comprehensive science mapping analysis,” J. Informetr., 2017, doi: 10.1016/j.joi.2017.08.007.
C. Chen, “CiteSpace II: Detecting and visualizing emerging trends and transient patterns in scientific literature,” J. Am. Soc. Inf. Sci. Technol., vol. 57, no. 3, pp. 359–377, Feb. 2006, doi: https://doi.org/10.1002/asi.20317. Scholar Publishing
N. J. van Eck and L. Waltman, “Software survey: VOSviewer, a computer program for bibliometric mapping,” Scientometrics, 2010, doi: 10.1007/s11192-009-0146-3.
E. Kouhsari et al., “The emergence of metronidazole and vancomycin reduced susceptibility in Clostridium difficile isolates in Iran.,” J. Glob. Antimicrob. Resist., vol. 18, pp. 28–33, Sep. 2019, doi: 10.1016/j.jgar.2019.01.027.
F. Khademi et al., “Resistance pattern of Helicobacter pylori strains to clarithromycin, metronidazole, and amoxicillin in Isfahan, Iran.,” J. Res. Med. Sci. Off. J. Isfahan Univ. Med. Sci., vol. 18, no. 12, pp. 1056–1060, Dec. 2013.
R. Li, L. Lu, Y. Lin, M. Wang, and X. Liu, “Efficacy and Safety of Metronidazole Monotherapy versus Vancomycin Monotherapy or Combination Therapy in Patients with Clostridium difficile Infection: A Systematic Review and Meta-Analysis.,” PLoS One, vol. 10, no. 10, p. e0137252, 2015, doi: 10.1371/journal.pone.0137252.
X. Di et al., “A meta-analysis of metronidazole and vancomycin for the treatment of Clostridium difficile infection, stratified by disease severity.,” Brazilian J. Infect. Dis. an Off. Publ. Brazilian Soc. Infect. Dis., vol. 19, no. 4, pp. 339–349, 2015, doi: 10.1016/j.bjid.2015.03.006.
P. Upcroft and J. A. Upcroft, “Drug targets and mechanisms of resistance in the anaerobic protozoa,” Clin. Microbiol. Rev., vol. 14, no. 1, pp. 150–164, 2001.
U. Loderstädt and H. Frickmann, “Antimicrobial resistance of the enteric protozoon Giardia duodenalis–A narrative review,” Eur. J. Microbiol. Immunol., vol. 11, no. 2, pp. 29–43, 2021.
S. S. Adeiza, M. G. Shuaibu, and A. B. Shuaibu, “Knowledge mapping of Nigeria’s scientific contribution to antimicrobial resistance research. A visualized investigation using VOS viewer and Cite Space,” Microbes Infect. Dis., vol. 5, no. 2, pp. 588–602, 2024.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Sondos Fouzi Elathram, Riad Mohammed Abdelrahman, Zinab Salah Ali, Ismail Adam Arbab, Mohsen Hussein Suliman, Ala Gamaleldin Khalifa, Eltieb Omer Ahmed, Sahar Ibrahim Gasmallah, Wafaa Ramadan Ahmed, Khalid Hamid Fadul, Mohammed Jalal, Chiamaka Linda Mgbechidinma, Taha Hussein Musa
This work is licensed under a Creative Commons Attribution 4.0 International License.
